Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 358

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 358
---
 AGREEMENT PROPOSAL. In reaching its decision to approve and declare advisable the Merger Agreement, the Mergers, the HCRX Asset Purchase Agreement, the Pacira Asset Purchase Agreement, the GigaGen Agreement and the Asset Sales, the Kineta Board of Directors, as described in the section entitled “The Mergers—Background of the Transactions”, held a number of meetings, consulted with Kineta’s senior management and its outside legal, and considered the business, assets and liabilities, results of operations, financial performance, strategic direction and prospects of Kineta and TuHURA. On December 11, 2024, after due consideration and consultation with Kineta’s senior management and outside legal counsel, the Kineta Board of Directors unanimously approved and declared advisable the Merger Agreement, and the Mergers and recommended that Kineta stockholders vote in favor of the adoption of the Merger Agreement. In making its determination, the Kineta Board of Directors focused on a number of factors, including the following (which are not necessarily presented in order of their relative importance to the Kineta Board of Directors):

| • |     | Stockholder Value: The transactions contemplated by the Merger Agreement provided the most value to                                                                                                                                               
 Kineta’s stockholders overall, considering both the potential to provide immediate liquidity to stockholders from the proceeds of the Asset Sales and the potential for current Kineta stockholders to realize long-term value as stockholders of 
 TuHURA following the Mergers;                                                                                                                                                                                                                     |

| • |     | Premium to Current Equity Price. The Merger Consideration to be paid by TuHURA consisting of a base cash                                                                                                                                             
 amount of $9,005,000 (consisting of a value of $15,000,000 minus the $5,995,000 advanced to Kineta under the Exclusivity Agreement) and $20 million of TuHURA Common Stock (less the sum of Kineta’s working capital deficit at the closing of       
 the Mergers and any working capital loans made by TuHURA to Kineta between the signing of the Merger Agreement and closing of the Mergers), which implied an equity value of $2.28 per share of Kineta Common Stock, based on TuHURA’s closing stock 
 price on November 25, 2024, the last full trading day prior to the announcement of a potential transaction and Kineta’s outstanding shares as of the same date, would provide Kineta stockholders with the opportunity to receive approximately